Breaking News, Financial News

Financial Report: Hospira

U.S. Specialty Injectable segment drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hospira 4Q Revenues: $1.1 billion (+4%) 4Q Earnings: $35.8 million (+7%) FY Revenues: $4.5 billion (+12%) FY Earnings: $333.2 million (loss of $8.3 million FY13) Comments: Growth in the quarter was driven by U.S. Specialty Injectable Pharmaceuticals (SIP), up 6% to $606.8 million, and Other Pharma sales, up 24% $130.1 million, offset by the expected decline of Precedex, docetaxel and Medication Management sales, related to the divestiture of the TheraDoc clinical surveillance software busin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters